Dabur

Refer to important disclosures at the end of this report

Recovery to be gradual; Maintain HOLD

- Dabur was witnessing some revival in growth during April and May led by gradual recovery in demand and rural growth has been marginally ahead of urban growth. However, June month has been witnessing destocking by distributor on account of GST.
- Except for core Ayurvedic portfolio of Rs1.5-2bn where the GST rate is higher at 12% v/s 7% earlier, the rest of the portfolio has been neutral to positive for the company.
- Loss in market share in categories like hair care and honey due to high competitive intensity seems to have bottomed out and with the likely recovery in overall demand growth, these segment will resume to growth in ensuing quarters. The company has a healthy pipeline of new products for H2FY18.
- We have revised our estimate to factor in the gradual recovery and model a flat revenue growth in H1FY18. We have cut our earnings estimate by 4.5%/2.6% for FY18E/FY19E. We maintain a HOLD rating with a price target of Rs 280/share.

April & May saw some traction but June impacted by destocking

Dabur was witnessing some revival in growth during April and May led by gradual recovery in demand. However, June month has been witnessing destocking by distributor on account of GST. Rural growth has been marginally ahead of urban growth. Except for core Ayurvedic portfolio of Rs1.5-2bn where the GST rate is higher at 12% v/s 7% earlier, the rest of the portfolio has been neutral to positive for the company. We understand from our channel check that company is compensating distributor for their loss on inventory as on 30th June 2017. Dabur has reduced the overall inventory at the distributor level post demon and will continue to do even during GST implementation, current inventory days is ~22 which will come down by 4-5 during GST implementation.

Share loss bottomed out; growth led by recovery & new launches

Loss in market share in categories like hair care and honey due to high competitive intensity seems to have bottomed out and with the likely recovery in overall demand growth, these segments will resume to growth in ensuing quarters. Company has healthy pipeline of new product launches in health care (diabetes, cholesterol & stress management), fruit drink, Ayurveda segment of hair oil and various other categories. These launches will be mainly in H2FY18 once the disruption in trade due to GST settles down.

Recovery to be gradual; Maintain HOLD

While, Dabur has a well-diversified portfolio it has been witnessing growth challenges in most of the segment. Muted category growth and competition has been the key headwinds We have revised our estimate to factor in the gradual recovery and model a flat revenue growth in H1FY18. We have cut our earnings estimate by 4.5%/2.6% for FY18E/FY19E to factor in gradual recovery in India business, muted international business and lower margins on account of higher ad spend. We maintain a HOLD rating with a price target of Rs 280/share.

Financial Snapshot (Consolidated)

(Rs mn)	FY15	FY16	FY17	FY18E	FY19E
Revenue	78,272	77,797	77,050	83,212	94,484
EBITDA	13,164	14,292	15,125	16,234	18,847
EBITDA Margin (%)	16.8	18.4	19.6	19.5	19.9
APAT	10,658	11,620	12,805	13,427	15,850
EPS (Rs)	6.1	6.6	7.3	7.6	9.0
EPS (% chg)	15.7	8.9	10.0	4.9	18.0
ROE (%)	35.5	30.9	28.4	25.3	26.9
P/E (x)	47.8	43.9	39.9	38.0	32.2
EV/EBITDA (x)	38.7	35.6	33.7	30.8	26.5
P/BV (x)	15.2	12.2	10.5	8.9	8.5

Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES.

Emkay[©]

СМР	Target Price
Rs 290 as of (June 22, 2017)	Rs 280 (∎) 12 months
Rating	Upside
HOLD (∎)	(3.4) %

Change in Estimates

EPS Chg FY1	8E/F	Y19E (%) (4	.5)/(2.6)
Target Price of	hang	e (%)		NA
Target Period	(Mon	ths)		12
Previous Rec	0			HOLD
Emkay vs Co	onsen	sus		
l	EPS E	stimate	S	
		FY	18E	FY19E
Emkay			7.6	9.0
Consensus			8.1	9.3
Mean Conser	isus T	P (12M)		Rs 302
Stock Details	5			
Bloomberg Co	ode		DA	ABUR IN
Face Value (F	₹s)			1
Shares outsta	Inding	(mn)		1,762
52 Week H/L			3	20 / 259
M Cap (Rs br	/USD	bn)	51	1 / 7.91
Daily Avg Vol	ume (nos.)	19	9,71,897
Daily Avg Tur	nover	(US\$ m	n)	8.5
Shareholding	g Patt	ern Mar	'17	
Promoters				68.0%
FIIs				20.0%
DIIs				5.8%
Public and Ot	hers			6.2%
Price Perform	nance	;		
(%)	1M	3M	6M	12M
Absolute	5	2	9	(6)
Rel. to Nifty	2	(5)	(9)	(20)
Relative pric	e cha	rt		
325 Rs				% ¹⁰
310 -				- 2
295	MA AN	l	.И	6
280 -	$\sqrt{100}$	W MON	~N~	-14
265 -	T T	Y . W	w.	Un -22
	Oct-16	Dec-16 Feb-	17 Apr-	
Source: Bloom				·
This report is sole following person(production of the	s) are r	esponsible	e for the	

Amit Purohit

amit.purohit@emkayglobal.com +91 22 66121340

Dhaval Mehta

dhaval.mehta@emkayglobal.com +91 22 66121284

Other key takeaways

- Honey share decline has bottomed out and the company is seeing customers coming back to them, In case of Hair Oil, Sarso Amla and other brands like Almond and Anmol has been witnessing healthly growth thereby ensuring improvement in overall market share.
- RED toothpaste continues to see healthy growth in high teens while newly launched RED Gel has also done extremely well. Tooth powder in oral care category continues to see a decline.
- Hajmola will see high innovation in ensuing quarters with launch of different variants like Gourmet, Amrut etc.





Exhibit 2: Trend in advertising spend



Source: Company, Emkay Research

Exhibit 3: Revision in earning estimate

	FY18E			FY19E		
Y/E, Mar (Rs. mn)	Earlier	Revised	% Change	Earlier	Revised	% Change
Revenues	85,328	83,212	-2.5	96,886	94,484	-2.5
EBITDA	16,787	16,234	-3.3	19,232	18,847	-2.0
EBITDA Margin (%)	19.7	19.5	-20 bps	19.9	19.9	10 bps
APAT	14,055	13,427	-4.5	16,273	15,850	-2.6
EPS	8.0	7.6	-4.5	9.3	9.0	-2.6

Source: Emkay Research

Key Financials (Consolidated)

Income Statement

Y/E Mar (Rs mn)	FY15	FY16	FY17	FY18E	FY19E
Revenue	78,272	77,797	77,050	83,212	94,484
Expenditure	65,108	63,505	61,925	66,978	75,637
EBITDA	13,164	14,292	15,125	16,234	18,847
Depreciation	1,150	1,332	1,429	1,510	1,582
EBIT	12,014	12,960	13,696	14,724	17,265
Other Income	1,581	2,172	2,984	2,782	3,209
Interest expenses	401	485	540	589	530
PBT	13,194	14,647	16,139	16,917	19,945
Тах	2,509	2,999	3,303	3,456	4,053
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	10,658	11,620	12,805	13,427	15,850
Adjusted PAT	10,658	11,620	12,805	13,427	15,850

Balance Sheet

Y/E Mar (Rs mn)	FY15	FY16	FY17	FY18E	FY19E
Equity share capital	1,757	1,759	1,762	1,762	1,762
Reserves & surplus	31,785	39,947	46,712	55,770	66,814
Net worth	33,541	41,706	48,474	57,532	68,575
Minority Interest	182	217	248	282	323
Loan Funds	7,336	7,971	9,153	8,103	7,053
Net deferred tax liability	587	1,162	1,465	1,465	1,465
Total Liabilities	41,646	51,056	59,339	67,381	77,417
Net block	19,274	17,727	20,006	20,196	20,114
Investment	18,335	26,931	33,548	33,548	33,548
Current Assets	23,454	24,634	23,757	32,811	36,946
Cash & bank balance	2,760	2,198	3,048	10,945	11,770
Other Current Assets	856	3,379	3,138	1,013	1,151
Current liabilities & Provision	19,417	18,237	17,971	19,174	21,498
Net current assets	4,036	6,397	5,786	13,638	15,448
Misc. exp	0	0	0	0	8,307
Total Assets	41,646	51,055	59,340	67,381	77,417

Cash Flow

Y/E Mar (Rs mn)	FY15	FY16	FY17	FY18E	FY19E
PBT (Ex-Other income) (NI+Dep)	11,613	12,475	13,156	14,135	16,735
Other Non-Cash items	(392)	(888)	0	0	0
Chg in working cap	(914)	(2,348)	1,764	45	(985)
Operating Cashflow	10,472	10,820	15,690	15,016	16,488
Capital expenditure	(2,538)	215	(3,707)	(1,700)	(1,500)
Free Cash Flow	7,934	11,035	11,983	13,316	14,988
Investments	(7,390)	(8,596)	(6,617)	0	0
Other Investing Cash Flow	(415)	25	(17)	0	(8,310)
Investing Cashflow	(8,762)	(6,183)	(7,358)	1,082	(6,600)
Equity Capital Raised	1,297	334	155	0	0
Loans Taken / (Repaid)	254	636	1,181	(1,050)	(1,050)
Dividend paid (incl tax)	(4,620)	(4,222)	(3,972)	(4,369)	(4,806)
Other Financing Cash Flow	(698)	(211)	(2,596)	(2,193)	(2,677)
Financing Cashflow	(4,168)	(3,949)	(5,772)	(8,201)	(9,063)
Net chg in cash	(2,458)	688	2,560	7,897	825
Opening cash position	5,194	2,760	2,198	3,048	10,945
Closing cash position	2,695	3,448	4,759	10,945	11,770

Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES.

Profitability (%)	FY15	FY16	FY17	FY18E	FY19E
EBITDA Margin	16.8	18.4	19.6	19.5	19.9
EBIT Margin	15.3	16.7	17.8	17.7	18.3
Effective Tax Rate	19.0	20.5	20.5	20.4	20.3
Net Margin	13.7	15.0	16.7	16.2	16.8
ROCE	35.8	32.6	30.2	27.6	30.0
ROE	35.5	30.9	28.4	25.3	26.9
RolC	62.2	61.0	61.3	64.5	74.0
Per Share Data (Rs)	FY15	FY16	FY17	FY18E	FY19E
EPS	6.1	6.6	7.3	7.6	9.0
CEPS	6.7	7.4	8.1	8.5	9.9
BVPS	19.1	23.7	27.5	32.7	34.2
DPS	2.0	2.2	2.3	2.5	2.7
Voluctions (v)	FY15	FY16	EV47	FY18E	EV40E
Valuations (x) PER	47.8	43.9	FY17 39.9	38.0	FY19E 32.2
P/CEPS	47.8	43.9 39.4	35.9	34.2	29.3
P/BV	43.1	39.4 12.2	10.5	34.2 8.9	29.3
EV / Sales	6.5	6.5	6.6	6.0	5.3
EV / EBITDA	38.7	35.6	33.7	30.8	26.5
Dividend Yield (%)	0.7	0.8	0.8	0.9	20.0
	0.7	0.8	0.0	0.9	0.5
Gearing Ratio (x)	FY15	FY16	FY17	FY18E	FY19E
Net Debt/ Equity	0.0	0.0	0.0	(0.2)	(0.2)
Net Debt/EBIDTA	0.0	(0.1)	(0.1)	(0.6)	(0.6)
Working Cap Cycle (days)	6.0	19.7	13.0	11.8	14.2
Growth (%)	FY15	FY16	FY17	FY18E	FY19E
Revenue	10.4	(0.6)	(0.9)	8.0	13.6
EBITDA	13.8	8.6	5.8	7.3	16.1
EBIT	13.5	7.9	5.7	7.5	17.3
PAT	16.6	9.0	10.2	4.9	18.0
Quarterly (Rs mn)	Q4FY16	Q1FY17	Q2FY17	Q3FY17	Q4FY17
Revenue	21,613	19,284	19,816	18,529	19,147
EBITDA	4,154	3,488	4,087	3,339	4,176
	.,	18.1	20.6	18.0	21.8
	19.2				
EBITDA Margin (%)	19.2 3 319		3 573	2 938	3 331
EBITDA Margin (%) PAT	3,319	2,927	3,573 2.0	2,938 1.7	
EBITDA Margin (%)			3,573 2.0	2,938 1.7	
EBITDA Margin (%) PAT EPS (Rs)	3,319	2,927			1.9
EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%)	3,319 1.9	2,927 1.7	2.0	1.7	1.9 Mar-17
EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%) Promoters	3,319 1.9 Mar-16	2,927 1.7 Jun-16	2.0 Sep-16	1.7 Dec-16	1.9 Mar-17 68.0
EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research	3,319 1.9 Mar-16 68.1	2,927 1.7 Jun-16 68.0	2.0 Sep-16 68.0	1.7 Dec-16 68.0	3,331 1.9 Mar-17 68.0 20.0 5.8

Source: Capitaline

RECOMMENDATION HISTORY TABLE

Date	Closing Price	ТР	Period (months)	Rating	Analyst
02-May-17	285	280	12m	Hold	Amit Purohit
31-Jan-17	276	280	12m	Hold	Amit Purohit
26-Oct-16	295	310	12m	Hold	Amit Purohit
22-Sep-16	284	330	12m	Hold	Amit Purohit
28-Jul-16	306	280	12m	Hold	Prashant Kutty
29-Apr-16	274	270	12m	Hold	Prashant Kutty
29-Jan-16	249	275	12m	Accumulate	Prashant Kutty
29-Oct-15	269	300	12m	Buy	Prashant Kutty
30-Jul-15	289	310	12m	Buy	Prashant Kutty
07-May-15	253	272	12m	Buy	Prashant Kutty
30-Jan-15	252	265	12m	Buy	Prashant Kutty
22-Dec-14	228	245	12m	Buy	Prashant Kutty

Source: Company, Emkay Research

RECOMMENDATION HISTORY CHART



Emkay Rating Distribution

BUY	Expected total return (%) (Stock price appreciation and dividend yield) of over 25% within the next 12-18 months.
ACCUMULATE	Expected total return (%) (Stock price appreciation and dividend yield) of over 10% within the next 12-18 months.
HOLD	Expected total return (%) (Stock price appreciation and dividend yield) of upto 10% within the next 12-18 months.
REDUCE	Expected total return (%) (Stock price depreciation) of upto (-) 10% within the next 12-18 months.
SELL	The stock is believed to underperform the broad market indices or its related universe within the next 12-18 months.

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

DISCLAIMERS AND DISCLOSURES: Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house.EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited(NSE), MCX Stock Exchange Limited (MCX-SX).EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her relative's financial interest in the subject company. (NO)

EGFSL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report.

Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: (NO)

EGFSL or its associates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of EGFSL or its associates during twelve months preceding the date of distribution of the research report and EGFSL may have co-managed public offering of securities for the subject company in the past twelve months.

The research Analyst has served as officer, director or employee of the subject company: (NO)

The Research Analyst has received any compensation from the subject company in the past twelve months: (NO)

The Research Analyst has managed or co-managed public offering of securities for the subject company in the past twelve months: (NO)

The Research Analyst has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months: (NO)

The Research Analyst has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months: (NO)

The Research Analyst has received any compensation or other benefits from the subject company or third party in connection with the research report: (NO)

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction. No part of this document may be distributed in chanad or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless